These findings offer new perspectives in the stratification of patients with HFpEF who have achieved target NT-proBNP levels as a result of conventional management and/or concomitant comorbidities such as obesity. The gene discussed is NPPB; the disease is obesity due to melanocortin 4 receptor deficiency.